Results 71 to 80 of about 499,108 (302)

Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer

Molecular Oncology, EarlyView.
A comprehensive genomic and proteomic analysis of cervical cancer revealed STK11 and STX3 as a potential biomarkers of chemoradiation resistance. Our study demonstrated EGFR as a therapeutic target, paving the way for precision strategies to overcome treatment failure and the DNA repair pathway as a critical mechanism of resistance.
Janani Sambath, Irene A. George, Srikanth S. Manda, Prasanth Ariyannur, Ekta R. Dhawale, Raja Sekhar Kommu, Rajan Datar, Darshana Patil, Vinita Trivedi, Manisha Singh, Kumar Prabhash, Sewanti Limaye, Richa Chauhan, Prashant Kumar   +13 more
wiley   +1 more source

Tyrosine Kinase Inhibitors

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007
The extraordinary success of imatinib for the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumors and subgroups of patients with hypereosinophilic syndrome and chronic myelomonocytic leukemia has greatly stimulated the development of small molecule inhibitors for targeted therapy of malignant diseases.
  +5 more sources

The impact of pausing Bruton Tyrosine Kinase inhibitor (BTKi) therapy versus continued therapy on vaccination immune response in patients with chronic lymphocytic leukaemia: the IMPROVE RCT

Efficacy and Mechanism Evaluation
Background Chronic lymphocytic leukaemia is the most common leukaemia subtype and associated with profound immunosuppression. Bruton Tyrosine Kinase inhibitors have revolutionised chronic lymphocytic leukaemia management; however, Bruton Tyrosine Kinase ...
Jonathan A Cook, Piers Patten, Nicholas Peckham, Paul Moss, Abhishek Abhishek, Vicki S Barber, Anne Francis, Lelia Duley, Robbert Hoogeboom, Brian J Willett, Gratian Vandici, Gareth Plested, Lucy Eldridge, Patrick Julier, Thomas Roberts, Marie Hodges, Helen M Parry   +16 more
doaj   +1 more source

Tyrosine kinase inhibitor-induced carotid stenosis: A case report

Leukemia Research Reports, 2019
Tyrosine kinase inhibitors are considered as highly effective and relatively safe drugs for the treatment of chronic myeloid leukemia. If several side effects on short and long term are well known and described, their involvement in the development of ...
Jeanne Hersant, Martine Gardembas, Georges Leftheriotis, Patrick Vandeputte, Pierre Abraham, Samir Henni   +5 more
doaj   +1 more source

Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells. [PDF]

, 2017
Aberrant cytokine signaling initiated from mutant receptor tyrosine kinases (RTKs) provides critical growth and survival signals in high risk acute myeloid leukemia (AML).
Arbiser, Jack L, Bradley, Heath L, Bunting, Kevin D, Kapur, Reuben, Metts, Jonathan, Shah, Neil P, Wang, Zhengqi   +6 more
core   +1 more source

Emerging role of ARHGAP29 in melanoma cell phenotype switching

Molecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster, Melanie Kappelmann‐Fenzl, Anja Katrin Bosserhoff, Nicole Rachinger   +3 more
wiley   +1 more source

Systemic treatment for hepatocellular carcinoma

Chronic Diseases and Translational Medicine, 2018
Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and
Manushi Aggarwal, Abeer Arain, Zhaohui Jin   +2 more
doaj   +1 more source

Phosphoproteomics identifies a bimodal EPHA2 receptor switch that promotes embryonic stem cell differentiation [PDF]

, 2020
Embryonic Stem Cell (ESC) differentiation requires complex cell signalling network dynamics, although the key molecular events remain poorly understood.
Budzyk, Manon, Bustos, Francisco, Fernandez-Alonso, Rosalia, Findlay, Greg M., Helbig, Andreas O., Hukelmann, Jens, Kumar, Pankaj, Lamond, Angus I., Lanner, Fredrik, Petsalaki, Evangelia, Zhou, Houjiang   +10 more
core   +2 more sources

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Tyrosine Kinase Inhibitor Resistance in Patients with Chronic Myeloid Leukemia: A 10-Year Study of BCR-ABL Gene Mutation Profile in Russia (2006–2016)

Клиническая онкогематология, 2018
Background. Kinase domain mutations of BCR-ABL gene is the most common cause of tyrosine kinase inhibitor resistance. Aim. To present the data on prognostic value of BCR-ABL mutation burden in Russian patients over the last 10 years.
Vera Vyacheslavovna Tikhonova, M. A. Isakov, V. A. Misyurin, Yu. P. Finashutina, L. A. Kesaeva, N. A. Lyzhko, I. N. Soldatova, N. N. Kasatkina, E. N. Misyurina, A. V. Misyurin   +9 more
doaj   +1 more source